Monday, June 23, 2025 | 04:10 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Vaccinating India

Covid-19 inoculations pose an unprecedented challenge

Coronavirus, vaccine, covid, drugs, Sepsivac, clinical trials
premium

SII plans to make around 300 mn doses of the Oxford Astrazeneca vaccine by December

Business Standard Editorial Comment New Delhi
One unintended benefit of the extended time drug-makers are taking to deliver a Covid-19 vaccine is that it offers the government the breathing space to plan a workable vaccine delivery programme in conjunction with the states. The dimensions of the issue are daunting because post-liberalisation India has not faced a public health challenge of this magnitude. In an interview to the The Indian Express, Nandan Nilekani outlined the task at hand: Reaching 1.3 billion people in two years amounts to delivering 2.6 billion vaccinations (assuming it is dual dose), or more than 3 million vaccinations a day. The numbers may